|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.67/-0.23
|
企业价值
36.99M
|
资产负债 |
每股账面净值
0.59
|
现金流量 |
现金流量率
--
|
损益表 |
收益
2.09M
|
每股收益
0.21
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/11 20:36 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products. |